Skip to main content
Sign In
 

Pulmonology - Research Funding


 

(listed alphabetically by Principal Investigator or by Section faculty member involved)

Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+*
Principal Investigator: Steven H. Abman, MD
Source: NHLBI, NIH - HL07670-19
Amount: $1,878,079
Term: 1999 - 2009

Consultant for RO1 Application from Dr. Vivek Balasubramaniam
Consultant: Steven H. Abman, MD
Source: NHLBI, NIH - R01
Amount: $250,000/yr
Term: 2008 - 2013

Genetic Basis for Impaired Angiogenic Signaling in BPD+
Principal Investigator: Steven H. Abman, MD
Source: NHLBI, NIH - 1R01 HL085703-01A1
Amount: $3,401,283
Term: 2008 - 2013

Mentor for NIH K08 Award for Dr. Theresa Grover
Mentor: Steven H. Abman, MD
Source: NHLBI, NIH - K08
Amount: $120,000/yr
Term: 2004 - 2009

Mentor for NIH K08 Award for Dr. Vivek Balasubramaniam
Mentor: Steven H. Abman, MD
Source: NHLBI, NIH - K08
Amount: $120,000/yr
Term: 2003 - 2008

Mentor for NIH K23 Award for Dr. Peter Mourani
Mentor: Steven H. Abman, MD
Source: NHLBI, NIH - K23
Amount: $120,000/yr
Term: 2005 - 2010

Novel Strategies for the Prevention and Treatment of Chronic Lung Disease in Premature Newborns+
Principal Investigator: Steven H. Abman, MD
Source: Thrasher Foundation - PN 200601-194
Amount: $441,786
Term: 2006 - 2009

Role of VEGF in Perinatal Pulmonary Hypertension+
Principal Investigator: Steven H. Abman, MD
Source: NHLBI, NIH - 2 R01 HL068702-06
Amount: $1,084,201
Term: 2007 - 2011

Soluble Guanylate Cyclase in PPHN
Principal Investigator: Steven H. Abman, MD
Source: Bayer Pharmaceuticals Corporation
Amount: $500,000/yr
Term: 2007 - 2008

Superoxide Dismutase (SOD) Treatment of PPHN++
Principal Investigator: John P. Kinsella, MD
Co-Investigator: Steven H. Abman, MD
Source: NHLBI, NIH - R21 HL085782-01A1
Amount: $250,000/yr
Term: 2006 - 2011

SCCOR Grant: Lung Vascular Disease in Infants and Children: Mechanisms and Treatmentº ***
Principal Investigator: Kurt R. Stenmark, MD
Source: NHLBI, NIH - P50 HL084923
Amount: $12,345,967
Term: 2006 - 2011

  • Project 1: Noninvasive Inhaled NO in Premature Newborns
    Principal Investigator: John P. Kinsella, MD
    Co-Investigator: Steven H. Abman, MD
    Amount: $2,457,532
  • Project 3: Advanced Imaging and Diagnostics for Pediatric Pulmonary Hypertension
    Principal Investigators: Robin Shandas, PhD, and D. Dunbar Ivy, MD
    Amount: $2,271,467
  • Project 4: Circulating Fibrocytes in Hyperoxic Lung Vascular Remodeling
    Principal Investigator: Kurt R. Stenmark, MD
    Co-Investigators: Maria Frid, PhD, and Eva N. Grayck, MD
    Amount: $2,038,122
  • Project 5: Hypoxia-Inducible Factors in Neonatal Pulmonary Hypertension
    Principal Investigator: Carl W. White, MD
    Co-Investigators: Aftab Ahmad, PhD, Steven H. Abman, MD, and Theresa R. Grover, MD
    Amount: $2,686,424
  • Core A: Administrative Core
    Principal Investigator: Kurt R. Stenmark, MD
    Amount: $531,250
  • Core B: Noninvasive Inhaled Nitric Oxide in Premature Newborns
    Principal Investigator: Ling-Yi Chang, MD
    Co-Investigator: Steven H. Abman, MD
    Amount: $795,448
  • Core C: Clinical Research Skills Development Core
    Principal Investigator: Steven H. Abman, MD
    Amount: $531,222

SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: NHLBI, NIH - P50 HL 57144
Amount: $6,415,929
Term: 2001 - 2006

  • Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
    Principal Investigator: Kurt R. Stenmark, MD
    Amount: $2,076,662
  • Project II: Inhaled NO and the Prevention of BPD
    Principal Investigator: Steven H. Abman, MD
    Co-Investigator: John P. Kinsella, MD
    Amount: $1,860,606
  • Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
    Principal Investigator: Peter L. Jones, PhD
    Amount: $1,456,087
  • Clinical Core
    Principal Investigator: John P. Kinsella, MD
    Co-Investigator: Steven H. Abman, MD
    Amount: $481,196
  • Administrative Core
    Principal Investigator: Kurt R. Stenmark, MD
    Amount: $446,045

Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $72,520
Term: 2004 - 2006

Clinical Proteomics Center in Lung Disease++ºº
Principal Investigator: Frank J. Accurso, MD
Source: NHLBI, NIH - U01HL081335-01
Amount: $4,216,147
Term: 2005 - 2009

  • Core A: Administrative
    Principal Investigator: Frank J. Accurso, MD
    Amount: $453,886

  • Core B: Clinical
    Principal Investigator: Steven H. Abman, MD
    Co-Investigators: John P. Kinsella, MD, and D. Dunbar Ivy, MD
    Amount: $862,397

  • Core C: Data Management
    Principal Investigator: Gary O. Zerbe, PhD
    Amount: $884,826

  • Core D: Laboratory
    Principal Investigator: Mark W. Duncan, PhD
    Amount: $1,251,968

  • Core E: Educational
    Principal Investigator: Laurie A. Shroyer, PhD
    Co-Investigator: Robin R. Deterding, MD
    Amount: $604,993

Cystic Fibrosis Care Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-08
Amount: $216,300
Term: 2008 - 2009

Cystic Fibrosis Care Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-07
Amount: $211,605
Term: 2007 - 2008

Cystic Fibrosis Care Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-06
Amount: $203,307
Term: 2006 - 2007

Cystic Fibrosis Foundation - Inflammatory Mediator Core
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Accurs03Y1
Amount: $104,545/yr
Term: 2007 - 2008

Cystic Fibrosis Foundation - Inflammatory Mediator Core
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Accurs03Y2
Amount: $96,859/yr
Term: 2006 - 2007

Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $35,151
Term: 2005 - 2006

The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $21,477
Term: 2005 - 2010

Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations, and the Safety of Long-Term Treatment with Pulmozyme (Dornase Alfa)
Principal Investigator: Frank J. Accurso, MD
Source: Genentech, Inc.
Amount: $343,253
Term: 1994 - present

First-Year Clinical Fellowship for Dr. Jerimiah Lysinger
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - LYSING05B0
Amount: $42,500/yr
Term: 2005 - 2007

First-Year Fellowship Award for Dr. Livia Veress
Mentor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - VERESS07B0
Amount: $42,500/yr
Term: 2007 - 2009

First-Year Fellowship Award for Dr. Tod Olin
Mentor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $42,500/yr
Term: 2008 - 2009

Fourth-Year Research Fellowship Award for Dr. Edith Zemanick: Early Staphylococcal and Polymicrobial Infection in Cystic Fibrosis
Mentor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $62,500/yr
Term: 2007 - 2008

A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: PTC Therapeutics, Inc.
Amount: $67,253
Term: 2005 - 2006

A Phase 3, Open-Label, Follow-Up Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR CF3)
Principal Investigator: Frank J. Accurso, MD
Source: CORUS Pharmaceuticals, Inc.
Amount: $54,083
Term: 2005 - 2006

Reproducibility of Ion Transport Measurements in Pancreatic Sufficient Individuals with CF
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS05A0
Amount: $129,408
Term: 2006

Therapeutics Development Award
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $126,000/yr
Term: 2007 - 2008

TCH Clinical Translational Research Center
Colorado Clinical and Translational Sciences Institute

Principal Investigator: Ronald J. Sokol, MD
Core Laboratory Medical Director: Frank J. Accurso, MD
Source: NCRR, NIH - UL 1 RR025780
Amount: $5,323,500
Term: 2008 - 2013

Advancing Newborn Medicine Grant Program
Principal Investigator: Christopher D. Baker, MD
Source: INO Therapeutics
Amount: $7,500/yr
Term: 2006 - 2007

Advancing Newborn Medicine Grant Program
Principal Investigator: Christopher D. Baker, MD
Source: Ikaria Pharmaceuticals
Amount: $3,750/yr
Term: 2007 - 2008

Fellow Career Development Award
Principal Investigator: Christopher D. Baker, MD
Source: American Thoracic Society
Amount: $50,000/yr
Term: 2008 - 2009

Colorado Career Development in the Genetics and Genomics of Lung Disease
Principal Investigator: Mark Geraci, MD
Co-Investigator: Christopher D. Baker, MD
Source: NHLBI, NIH - 5K12 HL090147-02
Amount: $100,000/yr
Term: 2008 - 2010

INO Therapeutics Research Grant
Principal Investigator: Vivek Balasubramaniam, MD
Source: INO Therapeutics
Amount: $40,000
Term: 2004 - 2006

Nonresident Lung Angiogenic Precursor Cells in BPD+
Principal Investigator: Vivek Balasubramaniam, MD
Source: NHLBI, NIH - 1R01 HL089262-01A1
Amount: $1,250,000
Term: 2008 - 2013

Quantification and Analysis of Endothelial Progenitor Cells in Term and Preterm Umbilical Cord Blood+
Principal Investigator: Vivek Balasubramaniam, MD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2007 - 2008

Role of Endothelial Progenitor Cells in the Development of BPD+
Principal Investigator: Vivek Balasubramaniam, MD
Source: American Thoracic Society - ATS-06-060
Amount: $100,000
Term: 2007 - 2008

Role of Nitric Oxide in Lung Vascular Development+
Principal Investigator: Vivek Balasubramaniam, MD
Source: INO Therapeutics, Inc. - BALAV2
Amount: $225,000
Term: 2006 - 2009

Role of Vascular Endothelial Growth Factor and Nitric Oxide in Lung Vascular Development+
Principal Investigator: Vivek Balasubramaniam, MD
Source: NHLBI, NIH - 1 K08 HL073893
Amount: $653,400
Term: 2003 - 2008

TCH ONE Step Second-Hand Smoke Initiative
Principal Investigator: Keith L. Cavanaugh, MD
Source: Colorado Department of Public Health and Environment
Amount: $187,651/yr
Term: 2006 - 2007

TCH ONE Step Second-Hand Smoke Initiative
Principal Investigator: Keith L. Cavanaugh, MD
Source: Colorado Department of Public Health and Environment
Amount: $116,274/yr
Term: 2007 - 2008

Colorado State Tobacco Education and Prevention Partnership
Principal Investigator: Keith L. Cavanaugh, MD
Source: Colorado Department of Public Health and Environment
Amount: $96,228
Term: 2005 - 2006

Changing Provider Behavior: Increasing Inhaled Steroids in Pediatric Asthma (CME Statewide Education Initiative)
Principal Investigator: Robin R. Deterding, MD
Co-Principal Investigators: Gwendolyn S. Kerby, MD, and Monica Jones Federico, MD
Source: Colorado Department of Public Health and Environment - FLA-PPG0700564
Amount: $515,279
Term: 2006 - 2009

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $162,548
Term: 2005 - 2008

Phase 3, International, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV1 of >85%
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $75,200/yr
Term: 2008 - 2009

Rare Lung Disease Consortium Subcontract
Principal Investigator: Bruce Trapnell, MD
Co-Investigator: Robin R. Deterding, MD
Source: NHLBI, NIH - 5 U54 RR019498-04
Amount: $32,000/yr
Term: 2007 - 2008

Recommendations for the Evaluation, Diagnosis, and Treatment of the Child with Suspected Interstitial Lung Disease
Principal Investigator: Geoff Kurland, MD
Co-Principal Investigator: Robin R. Deterding, MD
Source: American Thoracic Society
Amount: $12,500
Term: 2005 - 2006

Computerized Data Entry in Asthma Clinic
Principal Investigator: Monica J. Federico, MD
Source: Schramm Foundation
Amount: $20,000/yr
Term: 2008 - 2009

Reducing School Absence Due to Asthma Exacerbations in Denver Public School Children**
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Monica J. Federico, MD
Source: Colorado Department of Public Health and Environment / Colorado Tobacco Research Program - 06-FLA-00845 (awarded to National Jewish Health)
Amount: $21,780
Term: 2006 - 2009

Cerebral Impact of Childhood Sleep Apnea
Principal Investigator: Ann C. Halbower, MD
Source: NIH - K23 RR024257
Amount: $150,000/yr
Term: 2007 - 2012

Cerebral Impact of Childhood Sleep Apnea
Principal Investigator: Ann C. Halbower, MD
Source: TCH Research Institute
Amount: $58,514
Term: 2008 - 2009

Cerebral Impact of Childhood Sleep Apnea
Principal Investigator: Ann C. Halbower, MD
Source: Thomas Wilson Sanitarium for Children of Baltimore City
Amount: $15,000
Term: 2005 - 2007

Cancer League of Colorado Foundation Research Grant
Principal Investigator: Kirk C. Hansen, PhD
Source: Cancer League of Colorado Foundation - PN200803-043
Amount: $30,000
Term: 2008 - 2009

High-End Shared Instrumentation Grant for the Purchase of a LTQ FT-ICR Hybrid Mass Spectrometer
Principal Investigator: Kirk C. Hansen, PhD
Source: NCRR, NIH - 1 S10 RR023015-01
Amount: $1,067,480
Term: 2007 - 2008

Cancer Center Core Grant
Principal Investigator: Paul Bunn, PhD
Facility Manager: Kirk C. Hansen, PhD
Source: National Cancer Institute, NIH - 5 P30 CA046934
Amount: $60,557/yr (Facility Funding)
Term: 2006 - 2011

Identification of Cytoplasmic Proteins Interacting with the Mammary Cell-Transforming Domain of Epithelium-Specific Ets Transcription Factor 1 (Ese-1)
Principal Investigator: Arthur Gutierrez-Hartmann, MD
Co-Investigator: Kirk C. Hansen, PhD
Source: Breast Cancer Research Program, Department of Defense - BC051589
Amount: $299,761/yr
Term: 2006 - 2009

Identifying Extracelluar Matrix (ECM) Mediators of Tumor Cell Dormancy
Principal Investigator: Pepper J. Schedin, PhD
Co-Investigator: Kirk C. Hansen, PhD
Source: Breast Cancer Research Program, Department of Defense - BC051532
Amount: $300,000/yr
Term: 2006 - 2009

Proteomics and Genomics Hands-On Workshop: From Sample Preparation to Data Analysis
Principal Investigator: Nichole Reisdorph, MS, PhD
Investigator: Kirk C. Hansen, PhD
Source: NHLBI, NIH - T15 HL086386
Amount: $526,136/yr
Term: 2006 - 2010

Anaerobic Bacteria in Cystic Fibrosis
Principal Investigator: J. Kirk Harris, PhD
Source: Cystic Fibrosis Foundation - HARRIS08A0
Amount: $99,792/yr
Term: 2008 - 2011

Explore the Use of Quantitative PCR to Identify and Quantify CF Pathogens in Sputum Samples
Co-Principal Investigators: Norman R. Pace, PhD, and J. Kirk Harris, PhD
Source: Biological Sciences Initiative, University of Colorado Boulder
Amount: $2,000
Term: 2008 - 2009

Molecular and Bioinformatic Support for High-Throughput Sequencing and the Consortium for Comparative Genomics
Principal Investigator: David D. Pollock, PhD
Co-Principal Investigator: J. Kirk Harris, PhD
Source: Academic Enrichment Funds, UCSOM
Amount: $139,000
Term: 2008 - 2010

The Association between Emergency Department Resources and Pediatric Asthma-Related Quality Indicators
Consultant: Gwendolyn S. Kerby, MD
Source: American Lung Association
Amount: $20,000/yr
Term: 2007 - 2009

Lung Function as an Outcome Measure in Preschool Children with CF
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $196,752/yr
Term: 2005 - 2008

Spirometry as an Outcome Measure in Preschool Children with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $920,504
Term: 2005 - 2009

Neuroimmune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: NIH - R01 HL67818
Amount: $225,000/yr
Term: 2002 - 2007

Childhood Asthma Research and Education (CARE) Network**
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Ronina A. Covar, MD, Gary L. Larsen, MD, and Marzena E. Krawiec, MD
Source: NIH - HL64288
Amount: $4,732,241
Term: 2004 - 2006

Multicenter Trial to Validate Protein Biomarkers of a Pulmonary Exacerbation in CF
Principal Investigator: Scott D. Sagel, MD
Source: Cystic Fibrosis Foundation - SAGEL07A0
Amount: $594,998
Term: 2007 - 2010

Noninvasive Biomarkers of Proteolytic Activity in Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: NCRR, NIH - 5 K23 RR018611
Amount: $653,400/yr
Term: 2003 - 2009

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects with Genotype G551D
Principal Investigator: Scott D. Sagel, MD
Source: Vertex Pharmaceuticals
Amount: $109,617/yr
Term: 2007 - 2009

Quality Improvement-Learning and Leadership Collaborative IV
Principal Investigator: Scott D. Sagel, MD
Source: Cystic Fibrosis Foundation - SAGEL06QI0
Amount: $2,160
Term: 2006 - 2007

Safety and Efficacy of a Novel Antioxidant-Rich Multivitamin Supplement for Persons with CF
Principal Investigator: Scott D. Sagel, MD
Source: Yasoo Health Inc.
Amount: $93,782/yr
Term: 2007 - 2008

Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: INO Therapeutics, Inc., CTRC - INOT50
Amount: $27,000
Term: 2004 - 2009

Genetic Disorders of Mucociliary Clearance
Principal Investigator: Michael R. Knowles, MD
Site Investigator: Scott D. Sagel, MD
Source: NCRR, NIH - 1 U54 RR019480-01
Amount: $6,250,000 (Site Funding: $390,776)
Term: 2004 - 2009

Collaborative Program in Bronchopulmonary Dysplasia**
Principal Investigator: Carl W. White, MD
Source: NHLBI, NIH - 3 U01 HL 56263
Amount: $951,028
Term: 2003 - 2007

Hypoxia-Inducible Factors in Bronchopulmonary Dysplasia**
Principal Investigator: Carl W. White, MD
Source: NIH - 5 U01 HL056263-11
Amount: $152,000/yr
Term: 2003 - 2007

Lung Epithelial Cell Survival Signaling in Ozone in Cystic Fibrosis and Normals**
Principal Investigator: Carl W. White, MD
Source: NIH - 1 R01 ES014448-01
Amount: $1,068,750
Term: 2005 - 2010

Mechanisms of Sulfur Mustard Toxicity**
Principal Investigator: Carl W. White, MD
Source: National Institute of Environmental Health Science, NIH - U54 NS058081-01
Amount: $7,800,000
Term: 2006 - 2011

NOT-NS Medical Countermeasures to Chemical Terrorism**
Principal Investigator: Carl W. White, MD
Source: NIH - Supplemental ES012504
Amount: $78,000
Term: 2005 - 2006

Thioredoxin as a Mucolytic Agent in Cystic Fibrosis**
Principal Investigator: Carl W. White, MD
Source: Karasik Foundation
Amount: $35,000
Term: 2005 - 2006

Center for Respiratory Biodefense at National Jewish Health (Project 5): Sulfur Mustard Toxicity in Human Alveolar Epithelial Cells and Macrophages**
Principal Investigator: Robert J. Mason, MD
Project Leader: Carl W. White, MD
Source: Department of Defense/AMRMC - W81XWH-07-1-0550
Amount: $50,000
Term: 2008 - 2009

Mechanisms of Particulate-Induced Lung Injury (Project IV)**
Principal Investigator: Robert J. Mason, MD
Site Investigator: Carl W. White, MD
Source: Environmental Protection Agency - CR83084601
Amount: $83,840
Term: 2005 - 2006

Mechanisms of Sulfur Mustard Toxicity to Lung**
Principal Investigator: Brian Day, PhD
Co-Principal Investigator: Carl W. White, MD
Source: NIH - 5U54ES015678-030002
Amount: $45,000/yr
Term: 2005 - 2006

Cystic Fibrosis Foundation Harry Shwachman Young Investigator Award
Principal Investigator: Edith Zemanick, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $85,000/yr
Term: 2008 - 2011


+ Supporting research funding in the Pediatric Heart Lung Center
++ Supporting research funding in the Pediatric Heart Lung Center and Neonatology
* Supporting research funding in Critical Care Medicine
** Supporting research funding in National Jewish Health
*** Supporting research funding in Cardiology and the Center for Bioengineering
º Supporting research funding in Critical Care Medicine, Neonatology, the Pediatric Heart Lung Center and the Perinatal Research Center
ºº Supporting research funding in Cardiology

Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-16
Amount: $1,800,000
Term: 2004-2009

Clinical Proteomics Center in Lung Disease
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - U01HL081335-01
Amount: $4,216,147
Term: 2005-2009

  • Core A: Administrative
    Principal Investigator: Frank J. Accurso, MD
    Amount: $475,296
  • Core B: Clinical
    Principal Investigator: Steven H. Abman, MD
    Co-Investigator: John P. Kinsella, MD
    Co-Investigator: D. Dunbar Ivy, MD
    Amount: $908,829
  • Core C: Data Management
    Principal Investigator: Gary O. Zerbe, PhD
    Amount: $913,363
  • Core D: Laboratory
    Principal Investigator: Mark W. Duncan, PhD
    Amount: $1,268,104
  • Core E: Educational
    Principal Investigator: Laurie A. Shroyer, PhD
    Co-Investigator: Robin R. Deterding, MD
    Amount: $650,555

Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health - 1 R01 DK57755-027
Amount: $578,904
Term: 2001-2005

Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-05
Amount: $195,626
Term: 2005-2006

Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-04
Amount: $229,490
Term: 2004-2005

Cystic Fibrosis First-Year Clinical Fellowship for Jerimiah Lysinger, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - LYSING05B0
Amount: $42,000
Term: 2005-2006

Cystic Fibrosis First-Year Clinical Fellowship for Edith Towler-Zemanick, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - TOWLER04B0
Amount: $42,000
Term: 2004-2005

A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation Therapeutics, Inc.)
Estimated Amount: $54,680
Term: 2004-2005

Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $35,151
Term: 2005-2006

The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $21,477
Term: 2005-2010

Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $72,520
Term: 2004-2006

A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial with Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary Pseudomonas Aeruginosa Requiring Frequent Antibiotics (AIR CF2)
Principal Investigator: Frank J. Accurso, MD
Source: CORUS Pharmaceuticals, Inc.
Amount: $61,013
Term: 2005

A Phase 3, Open-label, Follow-Up Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR CF3)
Principal Investigator: Frank J. Accurso, MD
Source: CORUS Pharmaceuticals, Inc.
Amount: $54,083
Term: 2005-2006

A Study of the Safety and Pharmacokinetics of 552-02 Following Fourteen Days of Dosing by Inhalation in Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Parion Sciences, Inc.
Amount: $29,822
Term: 2005

A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: PTC Therapeutics, Inc.
Amount: $67,253
Term: 2005-2006

Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations and the Safety of Long-Term Treatment with Pulmozyme (Dornase Alfa)
Principal Investigator: Frank J. Accurso, MD
Source: Genentech, Inc.
Amount: $343,253
Term: 1994-present

The Role of Vascular Endothelial Growth Factor and Nitric Oxide in Lung Vascular Development+
Principal Investigator: Vivek Balasubramaniam, MD
Source: National Institutes of Health - 1 K08 HL073893-01
Amount: $653,400
Term: 2003-2008

INO Therapeutics Research Grant
Principal Investigator: Vivek Balasubramaniam, MD
Source: INO Therapeutics
Amount: $40,000
Term: 2004-2006

Colorado State Tobacco Education and Prevention Partnership
Principal Investigator: Keith L. Cavanaugh, MD
Source: State of Colorado
Amount: $96,228
Term: 2005-2006

Recommendations for the Evaluation, Diagnosis, and Treatment of the Child with Suspected Interstitial Lung Disease
Principal Investigator: Geoff Kurland, MD
Co-Principal Investigator: Robin R. Deterding, MD
Source: American Thoracic Society
Amount: $12,500
Term: 2005-2006

A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Pediatric Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $39,365
Term: 2005

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $123,589
Term: 2005-2006

Serum Biomarkers and Risk Factors for Alzheimer's Disease
Principal Investigator: Mark W. Duncan, PhD
Source: Orentreich Foundation
Amount: $50,000
Term: 2005-2006

Practical Utility of Desorption Mass Spectroscopy Techniques
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005

Control of Bacterial Toxins by Viruses and Plasmids
Principal Investigator: Randall Holmes, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 AI014107-3Q
Amount: $2,462,582
Term: 2005-2010

Viability Assay for Human Islet Transplantation
Principal Investigator: Mark Nicolls, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R21 DK070203-02
Amount; $770,000
Term: 2004-2006

Cancer Center Core Grant++
Principal Investigator: Paul Bunn, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 CA046934-17
Amount: $12,141,528
Term: 1988-2006

Mental Retardation and Development Disabilities Research Center++
Principal Investigator: Stephen I. Goodman, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 HD004024-35
Amount: $3,709,360
Term: 2003-2008

Phospholipid Dynamics in Membrane Assembly++
Principal Investigator: Dennis Voelker, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 GM032453-21
Amount: $2,500,000
Term: 2004-2008

Protein Expression Analysis in Cystic Fibrosis++
Principal Investigator: Mark W. Duncan, PhD
Source: Cystic Fibrosis Foundation
Amount: $871,604
Term: 2002-2005

Growth Factors and Signaling Pathways in Pulmonary Fibrosis++
Principal Investigator: Scott Worthen, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 HL073720-01
Amount: $2,561,838
Term: 2003-2007

Osmoregulated Proteins in the Inner Medulla++
Principal Investigator: Thomas Berl, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 DK66544-01
Amount: $250,000
Term: 2004-2009

Molecular Mechanism and Role of Corneal Adlehyde Dehydrogenase++
Principal Investigator: Vasilis Vasiliou, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 EY011490-06
Amount: $225,000
Term: 2004-2009

Practical Utility of Desorption Mass Spectroscopy Techniques++
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005

Modulation of Inflammation by Cholesterol and 3-Hydroxy-3 Coenzyme A Reductase Inhibitors: Role of the Lipid Raft++
Principal Investigator: Michael Fessler, MD
Co-Investigator: Mark W. Duncan, PhD
Source: American Heart Association
Amount: $197,000
Term: 2002-2007

Proteomics for Testing Hypotheses about Down Syndrome++
Principal Investigator: David Patterson, PhD
Principal Investigator: Mark W. Duncan, PhD (Consortium Subcontractor)
Source: National Institutes of Health - RO1 NS051539-01 A1
Amount: $770,000
Term: 2004-2008

Redefining the Major Peanut Allergens++
Principal Investigator: Stephen Dreskin, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases - 5 R01 AI052164-03
Amount: $500,000
Term: 2003-2006

Myocardial Myotonic Dystophy Protein Kinase Function++
Principal Investigator: Benjamin Perryman, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R01 HL064136-04
Amount: $445,950
Term: 2001-2005

Chemoprevention of Early Pulmonary Lesions in Mice by Anti-Inflammatory Drugs++
Principal Investigator: Al Malkinson, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Cancer Institute - 5 R01 CA096133-02
Amount: $340,245
Term: 2002-2005

Development and Regeneration of the Endocrine Pancreas++
Principal Investigator: John Hutton, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases - 5 U19 DK061248-03
Amount: $988,732
Term: 2001-2004

Validation of Protein Biomarkers in Cystic Fibrosis
Principal Investigator: Steven W. Hunsucker, PhD
Source: Cystic Fibrosis Foundation - HUNSUC05A0
Amount: $258,034
Term: 2005-2008

Spirometry as an Outcome Measure in Preschool Children with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $920,504
Term: 2004-2007

Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation)
Amount: $113,410
Term: 2003-2005

Neuro-Immune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL67818
Amount: $225,000/yr
Term: 2002-2006

Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Ronina A. Covar, MD, Gary L. Larsen, MD, and Marzena Krawiec, MD
Source: National Institutes of Health - HL64288
Amount: $4,732,241
Term: 2004-2006

Noninvasive Biomarkers of Proteolytic Activity in Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - K23 RR018611-01
Amount: $653,400
Term: 2003-2008

Genetic Disorders of Mucociliary Clearance
Principal Investigator: Michael R. Knowles, MD
Site Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - ORD #1 U54 RR019480-01
Amount: $6,250,000
Amount (Site Funding): $390,776
Term: 2004-2009

Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health, General Clinical Research Center, and INO Therapeutics, Inc. - INOT50
Amount: $34,020
Term: 2004-2006

SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $6,415,929
Term: 2001-2006

  • Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
    Principal Investigator: Kurt R. Stenmark, MD
    Amount: $2,076,662
  • Project II: Inhaled NO and the Prevention of BPD
    Principal Investigator: Steven H. Abman, MD
    Co-Investigator: John P. Kinsella, MD
    Amount: $1,860,606
  • Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
    Principal Investigator: Peter L. Jones, PhD
    Amount: $1,456,087
  • Clinical Core
    Principal Investigator: John P. Kinsella, MD
    Co-Investigator: Steven H. Abman, MD
    Amount: $481,196
  • Administrative Core
    Principal Investigator: Kurt R. Stenmark, MD
    Amount: $543,369

Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Seattle Children's Hospital and Regional Medical Center
Amount (projected): $72,520
Term: 2004-2005

Bioavailability of Yasoo Formulation: A Pharmacokinetic Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc. - Yasoo-003
Amount (projected): $67,436
Term 2004-2005

A Phase 2, Randomized, Double-Blind, Parallel Dose-Ranging Study of Oral TheraCLEC-Total In Cystic Fibrosis Subjects with Exocrine Pancreatic Insufficiency (TC-2A)
Principal Investigator: Jeffrey S, Wagener, MD
Source: Altus Biologics, Inc.
Amount: $182,955
Term: 2004-2005

A Phase 1 Single-Dose, Dose-Escalation Trial Comparing Safety, Pharmacokinetics, and Delivery Time of Tobramycin Powder for Inhalation (TPI Powder) Administered by the Nektar T-326 Dry Powder Inhaler Device (T-326 Inhaler) to Tobramycin Solution for Inhalation (TOBI® at 300 mg/5 ml) Administered by a PARI LC PLUS™ Jet Nebulizer/DeVilbiss PulmoAide™ Compressor in Cystic Fibrosis (CF) Patients
Principal Investigator: Jeffrey S. Wagener, MD
Source: Chiron Pharmaceuticals, Inc.
Amount: $37,810
Term: 2003-2005

Treatment of Cystic Fibrosis Patients with Antioxidant Solution: A Pilot Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc.
Amount: $67,436
Term: 2004-2005

National Institutes of Health, National Heart Lung and Blood Institute, Collaborative Program in Bronchopulmonary Dysplasia**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health, National Heart Lung and Blood Institute - 3 U01 HL 56263
Amount: $951,028
Term: 2003-2007

Mechanisms of Particulate-Induced Lung Injury (Project IV)**
Principal Investigator: Robert J. Mason, MD
Site Investigator: Carl W. White, MD
Source: Environmental Protection Agency - CR83084601
Amount: $83,840
Term: 2005-2006

Thioredoxin as a Mucolytic Agent in Cystic Fibrosis**
Principal Investigator: Carl W. White, MD
Source: Karasik Foundation
Amount: $35,000
Term: 2005-2006

Lung Epithelial Cell Survival Signaling in Ozone in Cystic Fibrosis and Normals**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 1 R01 ES014448-01
Amount: $1,068,750
Term: 2005-2010

NOT-NS Medical Countermeasures to Chemical Terrorism**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - Supplemental ES012504
Amount: $78,000
Term: 2005-2006


+ Supporting research funding in the Pediatric Heart Lung Center
++ Supporting research funding in the Pediatric Heart Lung Center and Neonatology
* Supporting research funding in Critical Care Medicine
** Supporting research funding in National Jewish Health
*** Supporting research funding in Cardiology and the Center for Bioengineering
º Supporting research funding in Critical Care Medicine, Neonatology, the Pediatric Heart Lung Center and the Perinatal Research Center
ºº Supporting research funding in Cardiology

Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-16
Amount: $1,800,000
Term: 2004-2009

Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-12
Amount: $1,605,925
Term: 1999-2004

Role of NO in the Regulation of Fetal Pulmonary Vasoreactivity and Growth*+
Principal Investigator: Steven H. Abman, MD
Source: March of Dimes Birth Defects Foundation - 6-FY00-124
Amount: $351,200
Term: 2000-2003

Inhaled Nitric Oxide in the Prevention of Chronic Lung Disease+
Principal Investigator: John P. Kinsella, MD
Co-Investigators: Steven H. Abman, MD, and Adam A. Rosenberg, MD
Source: National Institutes of Health, National Heart, Lung and Blood
Institute - R01 HL64857-01A1
Amount: $7,080,990
Term: 2000-2004

Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health - 1 R01 DK57755-027
Amount: $2,287,423
Term: 2001-2005

Effects of Pseudomonas aeruginosa on Inflammatory Gene Expression
Principal Investigator: David Rodman, MD
Co-Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFPN0004-071
Amount: $1,500,000
Term: 2001-2004

Airway Clearance in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS98AO
Amount: $876,805
Term: 1999-2004

Cystic Fibrosis Therapeutic Development Center
Amount (Site Funding): Frank J. Accurso, MD
Co-Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation - ACCURS98YO
Amount: $809,770
Term: 1998-2003

Project I-Airway Epithelial Cell Genomics and Pseudomonas aeruginosa Infection in Cystic Fibrosis
Principal Investigator: David Rodman, MD
Project I Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFRODMAN00V0
Amount (Funding for Project 1): $375,000
Term: 2001-2004

Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-03
Amount: $221,254
Term: 2003-2004

A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation Therapeutics, Inc.)
Estimated Amount: $54,680
Term: 2004-2005

Cystic Fibrosis First-Year Clinical Fellowship for Theresa Laguna, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - LAGUNA03B0
Amount: $42,000
Term: 2003-2004

Cystic Fibrosis First-Year Clinical Fellowship for Edith Towler-Zemanick, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - TOWLER04B0
Amount: $42,000
Term: 2004-2005

The Role of Vascular Endothelial Growth Factor and Nitric Oxide in Lung Vascular Development+
Principal Investigator: Vivek Balasubramaniam, MD
Source: National Institutes of Health - 1 K08 HL073893-01
Amount: $653,400
Term: 2003-2008

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects with Mild to Moderate Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Cystic Fibrosis Foundation Therapeutics Network
Amount: $99,057
Term: 2002-2003

Responsive Virtual Human Technology Research National Science Foundation Grant
Principal Investigator: Robin R. Deterding, MD
Source: Research Triangle Institute - NSF 00-126
Amount: $42,704
Term: 2001-2004

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Sources: Inspire Pharmaceuticals, Inc.
Amount: $37,627
Term: 2004-2005

Cancer Center Core Grant++
Principal Investigator: Paul Bunn, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 CA046934-17
Amount: $12,141,528
Term: 2001-2006

Mental Retardation and Development Disabilities Research Center++
Principal Investigator: Linda S. Crnic, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 HD004024-35
Amount: $3,709,360
Term: 2003-2008

Phospholipid Dynamics in Membrane Assembly++
Principal Investigator: Dennis Voelker, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 GM032453-21
Amount: $2,500,000
Term: 2004-2008

Protein Expression Analysis in Cystic Fibrosis++
Principal Investigator: Mark W. Duncan, PhD
Source: Cystic Fibrosis Foundation
Amount: $871,604
Term: 2002-2005

Redefining the Major Peanut Allergens++
Principal Investigator: Stephen Dreskins, MD, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 AI052164-2
Amount: $500,000
Term: 2003-2005

Growth Factors and Signaling Pathways in Pulmonary Fibrosis++
Principal Investigator: Scott Worthen, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 HL073720-01
Amount: $475,000
Term: 2003-2007

Osmoregulated Proteins in the Inner Medulla++
Principal Investigator: Thomas Berl, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 DK66544-01
Amount: $250,000
Term: 2004-2009

Molecular Mechanism and Role of Corneal Adlehyde Dehydrogenase++
Principal Investigator: Vasilis Vasiliou, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 EY011490-06
Amount: $225,000
Term: 2004-2009

Practical Utility of Desorption Mass Spectroscopy Techniques++
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005

Modulation of Inflammation by Cholesterol and 3-Hydroxy-3 Coenzyme A Reductase Inhibitors: Role of the Lipid Raft++
Principal Investigator: Michael Fessler, MD
Co-Investigator: Mark W. Duncan, PhD
Source: American Heart Association
Amount: $197,000
Term: 2002-2007

Proteomics for Testing Hypotheses about Down Syndrome++
Principal Investigator: David Patterson, PhD
Principal Investigator: Mark W. Duncan, PhD (Consortium Subcontractor)
Source: National Institutes of Health - RO1 NS051539-01 A1
Amount: $77,000
Term: 2004-2008

Spirometry as an Outcome Measure in Preschool Children with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $920,504
Term: 2004-2007

Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation)
Amount: $113,410
Term: 2003-2005

The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Genentech, Inc.
Amount: $3,045
Term: 2001-2004

Neuro-Immune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL67818
Amount: $225,000/yr
Term: 2002-2006

Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Ronina A. Covar, MD, and Gary L. Larsen, MD
Source: National Institutes of Health - HL64288
Amount: $600,000/yr
Term: 1999-2004

Noninvasive Biomarkers of Proteolytic Activity in Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - K23 RR018611-01
Amount: $653,400
Term: 2003-2008

Genetic Disorders of Mucociliary Clearance
Principal Investigator: Michael R. Knowles, MD
Site Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - ORD #1 U54 RR019480-01
Amount: $6,250,000
Amount (Site Funding): $390,776
Term: 2004-2009

Cystic Fibrosis Foundation Fourth-Year Clinical Fellowship Grant
Breath Condensate Collection in Children with Cystic Fibrosis

Principal Investigator: Scott D. Sagel, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - SAGEL02A0
Amount: $62,600
Term: 2002-2003

Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health, General Clinical Research Center, and INO Therapeutics, Inc. - INOT50
Amount: $34,020
Term: 2004-2006

SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $6,415,929
Term: 2001-2006

  • Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
    Principal Investigator: Kurt R. Stenmark, MD
    Amount: $2,076,662
  • Project II: Inhaled NO and the Prevention of BPD
    Principal Investigator: Steven H. Abman, MD
    Co-Investigator: John P. Kinsella, MD
    Amount: $1,860,606
  • Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
    Principal Investigator: Peter L. Jones, PhD
    Amount: $1,456,087
  • Clinical Core
    Principal Investigator: John P. Kinsella, MD
    Co-Investigator: Steven H. Abman, MD
    Amount: $481,196
  • Administrative Core
    Principal Investigator: Kurt R. Stenmark, MD
    Amount: $543,369

Inhaled Tobramycin in Young Cystic Fibrosis Patients
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: National Institutes of Health - 1R01 DK57755-03
Amount: $291,241
Term: 2000-2003

A Phase I, Open-Label Safety and Tolerability Study of Oral TheraCLEC
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Altus Biologics (TheraCLEC)
Amount: $206,610
Term: 2003-2004

Duration of Antimicrobial Treatment Effect Following Administration of Tobramycin for Inhalation (TOBI) in Young Children with Cystic Fibrosis
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation Therapeutics Network
Amount: $95,890
Term: 2002-2003

Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Seattle Children's Hospital and Regional Medical Center
Amount (projected): $72,520
Term: 2004-2005

Bioavailability of Yasoo Formulation: A Pharmacokinetic Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc. - Yasoo-003
Amount (projected): $67,436
Term 2004-2005

Single-Dose Escalation Study to Evaluate Safety of Nasal Administration of CFTR001 Gene Transfer Vector to Subjects with Cystic Fibrosis
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Copernicus Therapeutics
Amount: $55,849
Term: 2002-2003

Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations, and the Safety of Long-Term Treatment with Pulmozyme (Dornase Alfa)
Principal Investigator: Jeffrey S. Wagener, MD
Source: Genentech, Inc.
Amount: $21,625
Term: 1997-present

Clinical Targets in Hyperoxic Mitochondrial Injury
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 2 U01 HL56263
Amount: $667,257
Term: 1999-2004

Role of Hexokinase in Lung Adaptation to Oxidant Stress
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health 2 R01 HL52732
Amount: $619,257/yr
Term: 1999-2004


+ Supporting research funding in the Pediatric Heart Lung Center
++ Supporting research funding in the Pediatric Heart Lung Center and Neonatology
* Supporting research funding in Critical Care Medicine
** Supporting research funding in National Jewish Health
*** Supporting research funding in Cardiology and the Center for Bioengineering
º Supporting research funding in Critical Care Medicine, Neonatology, the Pediatric Heart Lung Center and the Perinatal Research Center
ºº Supporting research funding in Cardiology

Head CT in the Evaluation of 1st Afebrile Seizures
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, Louis C. Hampers, MD, MBA, Carol Okada, MD, and Rebecca Fastle, MD
Term: 2000-2004

Postreduction Management of Intussusception
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, and Shayne Bland, MSc
Term: 2000-2002

Emergency Medical Services for Children Partnership Grant
Principal Investigator: F. Keith Battan, MD
Source: US Department of Health and Human Services, Maternal and Child Health Bureau -
FLAEMS01-00250
Amount: $122,000
Term: 2000-2001

L.O.C.O. (Latinos Overcoming Cultural Obstacles) "Needs Assessment for The Children's Hospital"
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001

The Truth about Language Barriers
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Stephen Federico, MD
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001-ongoing

Jungle Mobile: A Mobile Injury Prevention Project for Children
Principal Investigator: Kathryn D. Emery, MD
Co-Investigators: Allison Hawkes, MD, MS, Theresa Rapstine, RN, and Victoria Cassenbaugh, RN
Term: 1998-ongoing

A Screening Tool for the Detection of Child Abuse in the Emergency Department Setting
Joint Project with the Child Advocacy Protection Team

Principal Investigator: Kathryn D. Emery, MD
Term: 2001

Seat Belt and Car Safety Seat Use in SUVs
Primary Investigator: Kathryn D. Emery, MD
Co-Investigators: Lisa Hardin Van Bramer, MD, and Kevin Raines, MD
Source: National Highway Traffic Safety Administration - STNH22-01-H-05-257
Amount: $350,000
Term: 2001-2003

Childhood Injury Prevention Concerns of Migrant and Seasonal Farm Workers in Weld County
Principle Investigator: Kathryn D. Emery, MD
Co-Investigator: S. Glenn Faries, MD
Source: Colorado Injury Control Research Center
Amount: $15,000
Term: 2002-2003

Domestic Violence Policies in Pediatric Emergency Departments
Principle Investigator: Kathryn D. Emery, MD
Co-Investigators: Sheila Sullivan, MD, Andrew P. Sirotnak, MD, and Stephanie Stronks-Knapp, MD
Term: 2002-ongoing

Development of an Injury-Free Coalition for Kids
Principal Investigator: S. Glenn Faries, MD
Co-Investigator: Kathryn D. Emery, MD
Term: 2001-ongoing

Resident Education in the Emergency Department
Principal Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Need for Atropine for Emergent Pediatric Intubations
Principal Investigator: Rebecca Fastle, MD
Co-Investigator: Mark G. Roback, MD
Term: 1999-ongoing

Resuscitation Teaching at Primary Care Centers
Principal Investigator: Margaret Ferguson, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-ongoing

Utility of Anaerobic Blood Cultures in a Pediatric Emergency Department
Principal Investigator: Stephen Freedman, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2003

PEM Collaborative Research Committee, Cerebral Edema and DKA
Principal Investigator: Nicole Glaser, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-2001

Comparison of Oral Prednisone vs. Dexamethasone in Pediatric Asthma
Principal Investigator: Richard A. Greenberg, MD
Co-Investigators: Genie E. Roosevelt, MD, MPH, and Gwendolyn S. Kerby, MD
Term: 2002-ongoing

Peak Flow vs. Spirometry in Acute Asthma
Principal Investigator: David Gutglass, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 1997-ongoing

A.C.C.E.S.S. for Latinos: After-Hours Call Center and Extended Spanish Service
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: Lauren Clark, PhD, RN, and Stephen Berman, MD
Term: 2001-2002

The Impact of Interpreters on Resource Utilization in a Pediatric Emergency Department
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Jennifer McNulty, MD
Term: 1999-2002

Physician-Based Practice Pattern Variations in the Management of AGE
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Elizabeth Powell, MD, MPH
Term: 2001-ongoing

Practice Variation in the Management of Croup
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 1999-2002

Regional After-Hours Urgent Care Provided by a Tertiary Children's Hospital
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 2001-2002

Booster Seat Project
Principal Investigator: Lisa Hardin Van Bramer, MD
Co-Investigator: Kathryn D. Emery, MD
Source: Emergency Medical Services and Kiwanis Pediatric Trauma Institute
Amount: $18,000
Term: 2001-2002

Association of Influenza with Bacterial Tracheitis
Principal Investigator: Ron L. Kaplan, MD
Co-Investigators: Mark G. Roback, MD, and Peggy Kelly, MD
Term: 2002-ongoing

Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Patients Birth to 48 Months Old with Reactive Airways Disease in an Acute Setting
Principal Investigator: Gwendolyn S. Kerby, MD
Co-Investigator: S. Glenn Faries, MD
Term: 2001-2002

Effect of Ondansetron on Ketamine Sedation-Associated Vomiting
Principal Investigator: William T. Langston, MD
Co-Investigators: Joseph E. Wathen, MD, and Mark G. Roback, MD
Source: The Children's Hospital Research Institute
Amount: $5,000
Term: 2002-ongoing

Effect of Medical Spanish Classes on Satisfaction of Hispanic Patients in Pediatric Emergency Department
Principal Investigator: Suzanne Mazor, MD
Co-Investigators: Vidya Chande, MD, Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 2000-2002

Interpretation of Traumatic Lumbar Punctures: Who Can Go Home?
Principal Investigator: Suzan Mazor, MD
Co-Investigators: Jennifer McNulty, MD, and Genie E. Roosevelt, MD, MPH
Term: 2001-ongoing

How Is Emergency Department Decision-Making Affected by the Existence of Reliable Follow-Up?
Principal Investigator: Jennifer McNulty, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 1999-2001

Decision Rules for Obtaining Radiographs in Pediatric Knee Injuries
Principal Investigator: Brian Moore, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Kathryn Emery, MD
Term: 1998-ongoing

Indications for Knee Radiographs in Pediatric Patients with Acute Knee Injuries/Validation of a Clinical Decision Rule
Principal Investigator: Brian Moore, MD
Co-Investigators: Carol Turner, MD, and Kathryn D. Emery, MD
Term: 2000-ongoing

Correlation of Hemolysis with Facticous Hyperkalemia
Principal Investigator: Heather Owens, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Acute Complication of Type 1 Diabetes in Children
Primary Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Mark G. Roback, MD, and Joan P. Bothner, MD
Term: 2001-ongoing

Childhood Pedestrian Injuries
Primary Investigator: Arleta B. Rewers, MD, PhD
Term: 2002-ongoing

Femur Fractures and Associated Injuries
Principal Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Kathryn D. Emery, MD, and F. Keith Battan, MD
Term: 2000-ongoing

Are Chest X-Rays Required for all First-Time Wheezers?
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Mark E. Anderson, MD, and John D. Strain, MD
Term: 1998-ongoing

Comparison of the Efficacy and Safety of Sedation Drugs Used in a Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Joseph E. Wathen, MD, and Joan P. Bothner, MD
Term: 1999-ongoing

IV vs. IM Ketamine Sedation in the Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Joseph E. Wathen, MD
Source: The Children's Hospital Research Institute
Amount: $35,000
Term: 2000-ongoing

Pediatric Resuscitation Practice and Success Rate
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Rebecca Fastle, MD
Term: 2000-ongoing

Predictors of Which Patients will Benefit from Observations vs. Hospital Admission
Principal Investigator: Genie E. Roosevelt, MD, MPH
Co-Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Randomized, Double-Blind Study of Intravenous Fluids With and Without Dextrose in the Treatment of Dehydration in Pediatric Patients with Vomiting and Ketosis
Principal Investigator: Genie E. Roosevelt, MD, MPH
Term: 2002-ongoing

The Effect of Dehydration on the QT Interval of Healthy Children
Principal Investigator: Carl Shaw, MD
Co-Investigators: Joseph E. Wathen, MD, and Michael S. Schaffer, MD
Term: 2001

The Prevalence of Urinary Tract Infections in Febrile Children with AGE
Principal Investigator: Carl Shaw, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Use of Complementary Medicine in Pediatric Patients with Asthma
Principal Investigator: Alison Siegel Tothy, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2002

Associations between Insurance Type and Pediatric Admission Rate in Colorado, 1993-1999: Is Managed Care Fulfilling Its Promise?
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and James K. Todd, MD
Term: 2000-ongoing

Associations of Parental Depression and Child Health Outcomes
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Allison Kempe, MD, John Steiner, MD, David Price, MD, and David Magid, MD
Term: 2002-ongoing

Comparison of the Longitudinal Marginal Cost, Morbidity and Mortality of Inflicted and Unintentional Head Injuries in Young Children in a Nationwide Sample of Children's Hospitals
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Costs of Childhood Physical Abuse: Comparing Inflicted and Unintentional Head Injuries in Colorado Inpatients Under Three Years Old
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Epidemiology of Pediatric Psychiatric Visits to US Emergency Departments, Based on the National Hospital Ambulatory Medical Care Survey 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Hospital-Level Predictors of Inefficiency Amongst Hospitalized Patients in New York State
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and Andrew Racine, MD, PhD
Term: 2000-ongoing

Management of Acute Gastroenteritis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Management of Bronchiolitis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1993-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Comparison of Fascia Iliaca Compartment Nerve Block to Traditional Systemic Analgesics for Femur Fractures in a Pediatric Emergency Department
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Glen Merritt, MD, Gaia Georgopoulos, MD, and F. Keith Battan, MD
Source: The Children's Hospital Research Institute
Amount: $17,594
Term: 2001-2004

Pediatric EKG Interpretation Accuracy by Pediatric Emergency Medicine Physicians
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Arleta Rewers, MD, PhD, Angela Yetman MD, and Michael Schaffer MD
Term: 2001-ongoing

A Randomized Trial of Telephonic vs. On-Site Language Interpretation in a Pediatric ED
Principal Investigator: Ethan S. Wiener, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing